

CURRICULUM VITAE
DAVID JOHN DODWELL BSc MB ChB FRCP MD FRCR MEWI

Consultant in Clinical Oncology
Institute of Oncology, Level 4 - Bexley Wing, St James Hospital, Leeds, LS9 7TF

PERSONAL RECORD

Date of Birth	22.05.59
Nationality	British
Marital Status	Married with three children
GMC Registration	Full - registration No. 2831833
Defence Society	Medical Protection Society
Present position	Consultant in Clinical Oncology - from Jan 1995

MEDICAL EDUCATION

1977 - 1983	Leeds University Medical School
--------------------	---------------------------------

QUALIFICATIONS

1980	BSc Honours 2 (i) Biochemistry in Relation to Medicine
1983	MB.ChB (Leeds)
1986	MRCP (UK)
1991	MD (Leeds)
1994	FRCR
1998	FRCP (Edinburgh)

CURRENT APPOINTMENT AND LOCAL ROLES

Consultant Clinical Oncologist	Leeds Cancer Centre/ Institute of Oncology St James Hospital
Visiting Professorship	Sheffield Hallam University (from 1-5-04)
Senior Clinical Research Fellow	Dept of Population Health - Oxford University

CLINICAL PRACTICE

This comprises a site-specialized breast oncology practice based at St James Hospital, Leeds. In conjunction with my clinical and specialist nurse colleagues we have developed a service with the elements of MDT practice and meetings, prospective organisation of data collection to facilitate audit and activity analysis and protocols for diagnosis, therapy, communication and integrated follow-up.

I see 520 new patients per year and accept 40 cross referrals. I supervise systemic therapy and radiotherapy for patients with early and recurrent disease.

MEDICO-LEGAL PRACTICE

I have been involved in medico-legal practice for over 20 years. I accept around 30-40 instructions per year, the great majority of which relate to the management of breast cancer. The impact of diagnostic delay and oncology practice, including drug treatment and radiotherapy feature most prominently. The split between defendant and claimant work is around 60%/40%. I have been a member of the Expert Witness Institute for around 8 years. I receive instructions from the major medical defence unions (MDU and MPS) as well as the

large legal firms they work with, including DACBeachcroft, Hempsons and others. I receive instructions from claimants' solicitors and from intermediary medicolegal service companies.

I have attended 70-80 legal conferences over the last 5 years and attended court on 5 occasions to give evidence. I have been involved in two criminal cases as an independent expert.

I have attended medicolegal educational courses in London, Manchester and Leeds.

MEMBERSHIP OF LEARNED SOCIETIES

Royal College of Physicians
Royal College of Radiologists
British Medical Association
British Institute of Radiology
British Breast Group
American Society of Clinical Oncology
Sloane Group
Expert Witness institute

NATIONAL RESPONSIBILITIES

Sloane group

I am lead oncologist on this group auditing the outcome of screen-detected DCIS within the UK. With data on over 12000 patients collected over 10 years we have published data on diagnostic processes, patterns of care, variability in surgical, endocrine and radiotherapeutic interventions, recurrence and mortality.

UK Breast Cancer Screening Audit Group

I am the oncologist on this group with responsibility to contribute and co-ordinate the audit function of the UK Breast Screening Programme. Data are collected and analysed concerning all aspects of UK breast screening including patterns of care, case volume and outcome. An annual report is produced.

Chemotherapy Board - Royal College of Radiologists (RCR)

I am a member of this group with responsibility for co-ordinating the functions and determining the policy of the RCR in relation to systemic therapies in oncology. I chaired the Site Orientated Electronic Network for breast oncology within the RCR

Joint Council for Clinical Oncology (JCCO)

I represent the RCR on the JCCO. This group allows liaison and co-operation between Clinical and Medical Oncology the two specialties involved in solid tumour oncology within the UK. The predominant functions of JCCO are service configuration and standards of care.

Clinical chemotherapy information group (CCIG)

I am chair of the CCIG which provides clinical input into the development and implementation of a nationally agreed national data set (SACT) to capture and analyze the use of systemic therapy in solid cancer and haematology. We published on early

mortality in a large cohort of breast and lung cancer patients in 2016 and are currently working on the analysis of outcomes following the use of CDF and other high cost drugs, chemotherapy use in end of life care and the impact of age on chemotherapy utilisation, toxicity and early mortality.

UK Breast Cancer Group (UKBCG)

I am a member of the organising committee for this UK breast oncology organisation, which is planning its fourth national meeting in November. The group represents medical and clinical oncology within the UK.

Breast Cancer Haven

I am on the national board of the charitable support organisation Breast Cancer Haven being involved in fundraising events and their educational programmes and providing senior clinical input as needed.

Senior Research Fellow – Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Nuffield Dept of Population Health – Oxford University

I work as part of the EBCTCG team and provide clinical oncology guidance to produce individual patient-level meta-analyses of clinically relevant questions in breast cancer local therapy. This involves identification of new radiotherapy and surgery questions to be answered by the EBCTCG data, liaison with collaborators, analysis, contextual interpretation and writing reports and scientific publications.

Project team NABCOP audit

I am the oncologist on this UK HQIP-funded audit of the management of breast cancer in older women.

CLINICAL RESEARCH

My own research interests include surgical, systemic and radiotherapeutic interventions in early breast cancer.

I am on the steering committees for the TACT, TACT 2, TANGO, ABC, Anglo-Celtic, Intergroup IES, EPO, Strontium, AZURE, POSNOC and LORIS trials. I sit on the Breast Systemic Therapy Trials Steering Committee for the Institute of Cancer Research – Royal Marsden Hospital.

PUBLICATIONS

I have published over 120 peer-reviewed papers on the management of breast cancer.